Law360, New York (May 25, 2012, 5:08 PM ET) -- House lawmakers moved quickly Thursday to prevent a possible roadblock to the U.S. Food and Drug Administration user fee bill, adding a new biosimilars provision that they hoped would cut the bill's costs before it comes up for a vote Wednesday.
The Congressional Budget Office, in a cost estimate released Thursday, found that the House version of the bill would increase budget deficits by $247 million over 10 years. Under House rules, bills that would increase the deficit must be offset by spending cuts or tax...
House Hopes To Cut FDA Bill Costs With Biosimilars Provision
To view the full article, take a free trial now.
